SCHEDULE 13G/A 0001123292-25-000366 0000882095 XXXXXXXX LIVE 3 Common Stock, par value $0.0001 per share 12/31/2025 0001840233 Xilio Therapeutics, Inc. 98422T100 828 Winter Street, Suite 300 Waltham MA 02451 Rule 13d-1(c) GILEAD SCIENCES, INC. DE 14517678 0 14517678 0 14517678 N 19.9 CO Items 5, 7, 9: Consists of (A) 6,860,223 shares of common stock, par value $0.0001 per share (the "Common Stock"), of Xilio Therapeutics, Inc. (the "Issuer") issued to the Reporting Person on March 28, 2024, (B) 485,250 shares of Common Stock issued to the Reporting Person on April 3, 2024, (C) 1,759,978 shares of Common Stock issued to the Reporting Person on December 18, 2024, and (D) 5,412,227 shares of Common Stock issuable upon exercise of pre-funded warrants to purchase Common Stock held by the Reporting Person. Item 11: Based on 67,540,930 shares of Common Stock issued and outstanding as of January 13, 2026, as disclosed in the definitive proxy statement on Schedule 14A filed by the Issuer with the Securities and Exchange Commission (the "SEC") on January 26, 2026. Xilio Therapeutics, Inc. 828 Winter Street, Suite 300, Waltham, Massachusetts, 02451 Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 Delaware Y 14,517,678 19.9 14,517,678 0 14,517,678 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. GILEAD SCIENCES, INC. /s/ Andrew D. Dickinson 02/12/2026